Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$12.34|
|52 Week High||US$4.62|
|52 Week Low||US$12.87|
|1 Month Change||29.35%|
|3 Month Change||72.59%|
|1 Year Change||149.80%|
|3 Year Change||174.22%|
|5 Year Change||n/a|
|Change since IPO||97.44%|
Recent News & Updates
|XAIR||US Medical Equipment||US Market|
Return vs Industry: XAIR exceeded the US Medical Equipment industry which returned 37.7% over the past year.
Return vs Market: XAIR exceeded the US Market which returned 36.2% over the past year.
Stable Share Price: XAIR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: XAIR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union.
Beyond Air Fundamentals Summary
|XAIR fundamental statistics|
Is XAIR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XAIR income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.18|
|Net Profit Margin||-3,551.98%|
How did XAIR perform over the long term?See historical performance and comparison
Is Beyond Air undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate XAIR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate XAIR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: XAIR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: XAIR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XAIR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XAIR is overvalued based on its PB Ratio (8.8x) compared to the US Medical Equipment industry average (4.7x).
How is Beyond Air forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XAIR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XAIR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XAIR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XAIR's revenue (66.4% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: XAIR's revenue (66.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XAIR's Return on Equity is forecast to be high in 3 years time
How has Beyond Air performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XAIR is currently unprofitable.
Growing Profit Margin: XAIR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XAIR is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare XAIR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XAIR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (40.5%).
Return on Equity
High ROE: XAIR has a negative Return on Equity (-68.39%), as it is currently unprofitable.
How is Beyond Air's financial position?
Financial Position Analysis
Short Term Liabilities: XAIR's short term assets ($41.0M) exceed its short term liabilities ($4.5M).
Long Term Liabilities: XAIR's short term assets ($41.0M) exceed its long term liabilities ($6.2M).
Debt to Equity History and Analysis
Debt Level: XAIR's debt to equity ratio (14.5%) is considered satisfactory.
Reducing Debt: XAIR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XAIR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XAIR has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 41.4% each year.
What is Beyond Air current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XAIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XAIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XAIR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XAIR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XAIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Lisi (50 yo)
Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since June 14, 2017. Mr. Lisi serves as Chief Executive Office...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD1.09M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Experienced Management: XAIR's management team is considered experienced (3.1 years average tenure).
Experienced Board: XAIR's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: XAIR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.7%.
Beyond Air, Inc.'s employee growth, exchange listings and data sources
- Name: Beyond Air, Inc.
- Ticker: XAIR
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$289.769m
- Shares outstanding: 23.95m
- Website: https://www.beyondair.net
Number of Employees
- Beyond Air, Inc.
- 825 East Gate Boulevard
- Suite 320
- Garden City
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:07|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.